Rapidly advancing biomarker research is adding much-needed clarity to the differential diagnosis of Alzheimer’s disease (AD), particularly in early disease, but there are delays in the detection and diagnosis of AD. To combat these delays and allow patients access to early interventions that may slow disease progression, it is imperative that health care professionals involved in AD/dementia care are aware of advances in AD diagnostics and are able to translate these advances in the real-world practice setting.
In this CME Outfitters Snack, expert faculty will discuss biomarker research findings presented at the Alzheimer’s Association International Conference (AAIC), review the identification and measurement of AD pathophysiology, examine a framework for evidencing biomarker profiles of AD, provide updates on prognostic performance and interpretation of biomarkers, and conduct a case-based discussion of clinical impacts and applications.
Interpret biomarker-based investigations to identify patients with AD pathology in clinical and research settings.
This activity is supported by an educational grant from Lilly.
Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs), physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians.)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Tangalos reports the following financial relationships:
Advisory Board: Acadia Pharmaceuticals Inc.; Biogen; and Eisai Inc.
Consultant: Cyclo Therapeutics, Inc. (DSMB); Genentech, Inc.; Prothena (DSMB); and Roche
Stock Shareholder (ownership interest): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc.
Dr. Zetterberg reports the following financial relationships:
Advisory Board/Consultant: AbbVie Inc.; Acumen Pharmaceuticals, Inc.; Alector, Inc.; Alzinova; ALZPath Inc.; Annexon Biosciences; Apellis Pharmaceuticals; Artery Therapeutics, Inc.; AZTherapies, Inc.; Cognito Therapeutics; Cognition Therapeutics; Denali Therapeutics; Eisai Europe Ltd; NervGen Pharma Corp.; Novo Nordisk; OptoCeutics; Passage Bio; Pinteon Therapeutics; Prothena; and Red Abbey
Speakers Bureau: AlzeCure Pharma; Biogen; and Cellectricon; Fujirebio; and Roche
Stock Shareholder (ownership interest): Co-founder and stock shareholder of Brain Biomarker Solutions in Gotheburg AB (BBS), which is a part of the GU Ventures Incubator Program
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).